Table 1 Baseline characteristics of patients with relapsed/refractory lymphoma initiating salvage chemotherapy in Lilongwe
From: Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi
Total (n = 21) | HIV+ (n = 13) | HIV- (n = 8) | |
|---|---|---|---|
Age, years | 40 (16–78) | 49 (16–63) | 22 (18–78) |
Male, n (%) | 12 (57%) | 8 (62%) | 4 (50%) |
Histologic diagnosis, n (%) | |||
Diffuse large B-cell lymphoma | 6 (29%) | 3 (23%) | 3 (38%) |
Burkitt lymphoma | 2 (10%) | ― | 2 (25%) |
Plasmablastic lymphoma | 2 (10%) | 2 (15%) | ― |
Aggressive B-cell NHL NOS | 8 (38%) | 8 (62%) | ― |
Classical Hodgkin lymphoma | 3 (14%) | ― | 3 (38%) |
Refractory, n (%) | 3 (14%) | 1 (8%) | 2 (25%) |
Relapsed, n (%) | 18 (86%) | 12 (92%) | 6 (75%) |
Time to relapse from first-line chemotherapy completion, months | 3.0 (0.7–19.4) | 3.0 (0.7–19.4) | 3.6 (0.8–8.1) |
Localized disease, n (%) | 12 (57%) | 10 (77%) | 2 (25%) |
Largest lymph node mass, cm | 6.5 (3–22) | 16 (5–35) | 11 (2–18) |
Performance status ≤2, n (%) | 18 (86%) | 12 (92%) | 6 (75%) |
White blood cells, 103/μL | 4.6 (2.7–18.6) | 4.4 (3.3–8.9) | 4.9 (2.7–18.6) |
Absolute neutrophil count, 103/μL | 2.9 (0.9–14.3) | 2.4 (0.9–6.3) | 3.0 (1.3–14.3) |
Hemoglobin, g/dL | 11.2 (6.0–14.7) | 12.2 (9.2–14.7) | 10.3 (6.0–14.0) |
Platelets, 103/μL | 332 (56–767) | 312 (204–655) | 353 (56–767) |
Serum creatinine, mg/dL | 0.7 (0.3–2.9) | 0.8 (0.4–2.9) | 0.6 (0.3–1.0) |
eGFR <60 mL/min/1.73m2, n (%) | 1 (5%) | ― | 1 (13%) |
CD4 count if HIV+, cells/μL | ― | 139 (12–529) | ― |
HIV RNA <400 copies/mL if HIV+, n (%) | ― | 11 (85%) | ― |